Introduction
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), presents in highly variable clinical forms ranging from
a mild upper respiratory tract infection to severe respiratory failure necessitating
mechanical ventilation.[1 ]
[2 ] The disease primarily affects the respiratory system, however, especially in severe
cases, multiple organ systems may be involved.[1 ]
[2 ] In severe COVID-19, pathological overproduction of proinflammatory cytokines (termed
cytokine storm) has been described; the consequent systemic hyperinflammation is responsible
for most detrimental effects of the disease.[3 ]
[4 ] In parallel with the proinflammatory changes, a prothrombotic state is also present,
indicated by an increased risk of venous, arterial, and microvascular thrombotic events
and by characteristic changes in laboratory parameters, such as elevated fibrinogen
and D-dimer levels.[1 ]
[2 ]
[5 ]
[6 ] The concentration of von Willebrand factor (VWF) is increased,[7 ]
[8 ]
[9 ]
[10 ] whereas the activity of a disintegrin and metalloproteinase with a thrombospondin
type 1 motif, member 13 (ADAMTS13) metalloprotease—responsible for cleaving ultra-large
VWF multimers—is decreased,[11 ]
[12 ]
[13 ]
[14 ] resulting in an imbalance of the VWF-ADAMTS13 axis,[12 ]
[15 ]
[16 ]
[17 ] which was associated with a higher severity and mortality of COVID-19.[11 ]
[14 ]
[18 ]
[19 ]
[20 ]
[21 ]
Besides that of VWF, concentrations of further endothelial markers are also increased
in COVID-19,[8 ]
[18 ]
[22 ]
[23 ] indicating a role of altered endothelial cell function in the pathogenesis of severe
COVID-19 disease. Endothelial cells can directly be infected by the SARS-CoV-2 virus
via their angiotensin-converting enzyme 2 receptors[24 ]; moreover, they are important target cells of inflammatory mediators, which are
abundant in severe COVID-19.[3 ]
[4 ] The consequential endothelial activation and dysfunction may result in hemostatic
abnormalities,[25 ] and in the dysregulation and overactivation of multiple plasma enzyme systems, including
the complement system.[26 ] The complement system was indeed found to be activated in COVID-19; the extent of
complement activation was associated with the severity and outcome of the COVID-19
disease.[27 ]
[28 ]
[29 ] Furthermore, a strong correlation was described between markers of endothelial and
complement activation in COVID-19,[22 ] which may reflect the fact that the two processes are linked on multiple levels:
endothelial dysfunction facilitates complement activation, whereas complement anaphylatoxins
and other activation products may in turn perturb endothelial function.[30 ]
Based on the above, we hypothesized that the pathological activation of endothelial
cells and the complement system contribute jointly to the pathogenesis of the COVID-19
disease.
Accordingly, or aim was to determine the VWF antigen (VWF:Ag) concentration, VWF collagen
binding activity (VWF:CBA), ADAMTS13 activity (ADAMTS13:Ac), and their ratios in hospitalized
COVID-19 patients, and to investigate how these parameters and their constellations
with markers of complement activation relate to disease severity and in-hospital mortality
in COVID-19.
Methods
Patient Selection, Outcomes, and Definitions
To enroll a cohort of adult (above 18 years of age) hospitalized COVID-19 patients,
we screened and sampled 110 adult patients who were treated for suspected COVID-19
disease in two tertiary referral hospitals in Budapest between April 20 and July 2,
2020. One hundred and two of the above patients with confirmed COVID-19 infection—positive
reverse transcription polymerase chain reaction (RT-PCR) test result for SARS-CoV-2
in at least one nasopharyngeal swab sample—were included in our study.
The enrolled hospitalized patients were categorized according to the maximal (peak)
severity of the COVID-19 disease—and also according to the severity at sampling—in
agreement with the World Health Organization (WHO) Ordinal Scale for Clinical Improvement
(https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf ). Patients who did not need oxygen therapy formed the HOSP (WHO-3: hospitalized,
no oxygen therapy) subgroup. Those patients who received oxygen support, but did not
require intubation and mechanical ventilation or admission to intensive care unit
(ICU) formed the HOSP + O2 (WHO-4: oxygen by mask or nasal prongs) subgroup. The severity
of the above cases was considered moderate, while fatal cases and cases requiring
ICU admission were considered severe. Surviving severe patients constituted the ICU
(WHO-6/7: intubation and mechanical ventilation ± additional organ support) subgroup,
whereas the deceased patients comprised the FATAL (WHO-8: death) severity subgroup.
Twenty-six volunteers, who were registered to donate convalescent plasma in a clinical
trial and had evidence of a previous COVID-19 disease (positive SARS-CoV-2 RT-PCR
at the time of the disease) not requiring hospitalization, were sampled and included
in the convalescent phase as a patient control group. The scheme of patient and control
subject enrolment is represented in [Supplementary Fig. S1 ] (available in the online version).
Digital hospital records were available for all enrolled patients; these were used
for the collection of the necessary clinical, radiological, and basic laboratory data.
The study was conducted in accordance with the Declaration of Helsinki and its subsequent
revisions, and was approved by the Hungarian Scientific and Research Ethics Committee
(ETT-TUKEB; No. IV/4403–2/2020/EKU). Written informed consent was obtained from the
patients and control subjects, or from the closest relative available, if the patient
was unable to give informed consent.
Samples
Blood samples were drawn from the antecubital vein or from a central venous catheter,
and were immediately transferred to the processing laboratory, where the cells and
the supernatant—serum, citrate-, and ethylenediaminetetraacetic acid-anticoagulated
plasma—were separated by centrifugation. Serum and plasma aliquots were immediately
frozen and stored at –70°C until measurements.
Only one sample per patient was included into the study, if more samples were available,
the one taken at the most severe clinical stage was included. The median time from
hospital admission until sample collection was 3 days (interquartile range: 1–7 days).
Laboratory Determinations
ADAMTS13:Ac was determined by a fluorescence resonance energy transfer assay using
the FRETS-VWF73 substrate, as described earlier.[31 ]
VWF:Ag concentration and VWF:CBA were measured by in-house sandwich enzyme-linked
immunosorbent assay methods described earlier.[32 ]
Both parameters were expressed as percentages, where the ADAMTS13:Ac, VWF:Ag, and
VWF:CBA value of a citrated plasma pool of healthy human individuals was regarded
as 100%. The VWF:Ag level of our citrated plasma pool was essentially similar (1.033 IU/mL)
to that of a commercially available calibrator (TECHNOZYM vWF:Ag Calibrator Set, Technoclone
GMBH, Vienna, Austria).
Determination of complement parameters was described earlier.[29 ]
Further laboratory data were extracted from hospital records.
Statistical Analyses
Categorical data are reported as frequencies (%); chi-square and Fisher's exact tests
were used to compare categorical data between groups. Most continuous variables showed
skewed distributions, so these data were presented as median and interquartile range,
and nonparametric tests were used: Mann–Whitney test for the comparison of two independent
groups, Kruskal–Wallis test with Dunn's post-test for the comparison of more than
two independent groups, and Spearman's rank correlation test for analyzing the correlations
between continuous variables. Cases with missing data were excluded pairwise. Receiver
operating characteristic (ROC) curves were generated and analyzed to determine optimal
cutoff points for transforming continuous variables into binary categorical variables.
Uni- and multivariable logistic regression models were built to assess the effects
of predictor variables on disease severity, and uni- and multivariable Cox proportional
hazard models were used to assess the effects of various clinical and laboratory parameters
on in-hospital mortality. Survival was defined as time from hospitalization until
the last follow-up visit before September 5, 2020, or until death (all-cause, in-hospital
mortality). Kaplan–Meier curves were generated to show the occurrence of primary events
plotted against time. Regression models were adjusted for a baseline model consisting
of age, the number of comorbidities, and C-reactive protein (CRP) concentrations.
The baseline model was the final, best-fitting model built in a conditional forward
stepwise manner based on age, the number of comorbidities, and the following laboratory
parameters associated with disease severity: lymphocyte count, CRP, D-dimer, and interleukin-6
(IL-6) levels. Statistical interaction, analyzed in Cox proportion hazard models,
means that the association of a variable with another is dependent on a third variable.
Statistical calculations were performed by GraphPad Prism 9 (GraphPad Softwares Inc.,
La Jolla, California, United States), Statistica (version 13.5.0.17, TIBCO Software
Inc., Palo Alto, California, United States), and IBM SPSS Statistics 27 (IBM Corporation,
Armonk, New York, United States) software.
Results
Description of the Patient Cohort and Severity Subgroups
A total of 102 hospitalized COVID-19 patients were enrolled in our study cohort ([Supplementary Fig. S1 ], available in the online version). In addition, 26 plasma donors in the convalescent
phase who were outpatients at the time of a previous SARS-CoV-2 infection (symptom
onset median 54 [range: 26–74] days before sampling) were included as a patient control
group (CONTR).
Hospitalized patients (n = 102) were divided into subgroups based on the peak disease severity ([Supplementary Fig. S1 ], available in the online version).
Twenty-seven patients did not need oxygen therapy during their hospital stay; these
patients formed the HOSP subgroup. Thirty-three patients who received oxygen support,
but did not require intubation and mechanical ventilation or admission to ICU, formed
the HOSP + O2 subgroup. Thirty patients required intubation and mechanical ventilation,
these and further eight patients were admitted to the ICU. Seventeen of the above
patients survived, they composed the ICU subgroup. Twenty-five patients died during
their hospital stay, the deceased patients comprised the FATAL subgroup. None of the
patients in our cohort were treated by noninvasive ventilation or high-flow oxygen
therapy (WHO-5).
Demographic, anamnestic, clinical, and laboratory parameters in the above outlined
peak severity subgroups are summarized in [Table 1 ]. (An alternative classification based on the disease severity at the time of sampling
was also performed; the description and basic laboratory parameters of these groups
are shown in [Supplementary Table S1 ], available in the online version.)
Table 1
Basic characteristics of COVID-19 patients
Variables
Total hospitalized, n = 102
Hospitalized, no oxygen support, n = 27
(HOSP)
Hospitalized, with nasal oxygen support, n = 33
(HOSP + O2)
ICU,
n = 17
Fatal,
n = 25
Control,
n = 26
p -Value[a ]
Male sex, % (n )
54.9 (56)
63.0 (17)
60.6 (20)
47.1 (8)
44.0 (11)
57.7 (15)
0.429
Age (median, IQR)
67 (56–76)
57 (42–69)
67 (63–78)
59 (50–68)
76 (72–80)
45 (34–54)
< 0.0001
Comorbidities[b ]
Total number of comorbidities (median, IQR)
2 (1–4)
2 (1–3)
2 (2–3)
2 (1–3)
4 (2–4)
0 (0–1)
0.016
Hypertension, % (n )
64.7 (66)
48.2 (13)
66.7 (22)
64.7 (11)
80.1 (20)
26.9 (7)
0.118
Chronic pulmonary disease, % (n )
21.6 (22)
11.1 (3)
18.2 (6)
23.6 (4)
36.0 (9)
0.0 (0)
0.165
Diabetes mellitus, % (n )
24.5 (25)
14.8 (4)
24.2 (8)
11.8 (2)
44.1 (11)
3.8 (1)
0.046
Chronic heart disease, % (n )
33.3 (34)
22.2 (6)
42.4 (14)
17.7 (3)
44.0 (11)
0.0 (0)
0.117
Malignant disease, % (n )
23.0 (23)
15.4 (4)
6.3 (2)
47.1 (8)
36.1 (9)
0.0 (0)
0.003
Other comorbidity, % (n )[b ]
86.3 (88)
96.3 (26)
87.8 (28)
64.7 (11)
92.0 (23)
3.8 (1)
0.885
Presenting symptoms
Delay between first symptom and blood sampling, days (median, IQR)
4.0 (1–9)
12.5 (8–28)
8.5 (6–15)
10.0 (7–28)
6.0 (3–16)
−
0.136
Complications
Respiratory failure necessitating mechanical ventilation, % (n )
29.4 (30)
0.0 (0)
0.0 (0)
58.8 (10)
80.1 (20)
0.0 (0)
< 0.0001
Macrothromboembolic complications, % (n )
8.8 (9)
0.0 (0)
0.0 (0)
41.2 (7)
8.0 (2)
0.0 (0)
< 0.0001
Acute kidney injury (KDIGO: 2–3), % (n )
11.7 (12)
0.0 (0)
6.1 (2)
5.9 (1)
36.0 (9)
0.0 (0)
0.002
Laboratory findings (median, IQR)
Neutrophil granulocyte count (2–7.5 G/L)
4.5 (3.0–6.1)
3.8 (2.8–5.1)
3.8 (2.9–5.9)
5.0 (3.2–6.1)
6.1 (2.1–10.0)
3.9 (3.0–4.6)
0.0100
Lymphocyte count (1.5–4 G/L)
1.1 (0.9–1.7)
1.6 (1.0–2.2)
1.5 (1.0–1.9)
0.9 (0.8–1.3)
0.8 (0.5–1.1)
2.0 (1.8–2.4)
< 0.0001
Interleukin 6 (2–4.4 pg/mL)
27.6 (9.7–72.1)
12.5 (5.6–24.5)
27.8 (9.5–63.8)
40.1 (14.3–51.3)
90.4 (34.6–267.3)
1.7 (1.1–2.5)
< 0.0001
C-reactive protein (< 10 mg/L)
58.5 (15.0–131.4)
11.6 (5.6–41.0)
36.8 (17.5–88.6)
111 (61.3–169.1)
149.1 (54.9–196.8)
1.3 (0.3–2.5)
< 0.0001
Platelet count (150–400 G/L)
229 (170–293)
242 (190–288)
233 (182–379)
229 (187–257)
191 (131–285)
224 (199–249)
0.2266
INR (0.9–1.15)
1.08 (0.99–1.19)
1.02 (0.98–1.10)
1.02 (0.98–1.11)
1.12 (1.04–1.22)
1.17 (1.07–1.48)
0.98 (0.94–1.02)
0.0030
Activated partial thromboplastin time (28–40 s)
33.0 (30.0–38.9)
33.0 (29.9–39.4)
31.2 (30.0–34.9)
33.7 (30.9–40.2)
33.9 (30.0–38.6)
34.4 (30.1–38.3)
0.8500
Thrombin time (15.8–24.9 s)
21.9 (17.3–27.7)
16.0 (15.0–19.8)
17.9 (17.0–22.8)
21.2 (17.6–30.3)
26.4 (23.1–28.1)
20.3 (19.6–20.7)
0.0349
Fibrinogen (2.8–4.7 g/L)
5.7 (4.1–6.6)
4.9 (4.1–5.6)
5.7 (4.6–6.5)
6.4 (5.5–7.8)
5.0 (3.9–6.5)
3.7 (3.0–4.2)
0.1171
D-dimers (< 500 ng/mL)
1357 (770–2,201)
1460 (610–2,210)
851 (530–1,526)
1658 (912–3,080)
1430 (1,106–4,380)
207 (158–453)
0.009
VWF and ADAMTS13 results (median, IQR)
VWF:Ag (%)
294 (200–396)
200 (130–272)
270 (200–346)
373 (240–523)
387 (304–496)
102 (83–144)
< 0.0001
VWF:CBA (%)
212 (155–325)
172 (105–246)
211 (155–254)
268 (176–356)
298 (199–433)
102 (71–117)
0.0022
VWF:CBA/VWF:Ag
0.82 (0.68–1.00)
0.94 (0.71–1.05)
0.80 (0.68–0.97)
0.80 (0.72–1.04)
0.80 (0.55–0.94)
0.94 (0.75–1.04)
0.5178
ADAMTS13:Ac (%)
67 (46–95)
99 (65–122)
74 (62–92)
55 (40–71)
43 (32–56)
96 (85–115)
< 0.0001
VWF:Ag/ADAMTS13:Ac
3.9 (2.5–8.7)
2.1 (1.6–3.6)
3.5 (2.5–5.0)
5.7 (3.9–14.8)
11.4 (5.8–13.8)
1.1 (0.9–1.3)
< 0.0001
VWF:CBA/ADAMTS13:Ac
3.4 (1.9–7.0)
2.0 (1.2–3.5)
2.6 (1.8–4.2)
5.0 (2.9–11.0)
7.0 (4.5–12.6)
1.0 (0.8–1.3)
< 0.0001
Abbreviations: ADAMTS13:Ac, a disintegrin and metalloproteinase with a thrombospondin
type 1 motif, member 13 activity; ICU, intensive care unit; INR, international normalized
ratio; IQR, interquartile range; VWF:Ag, von Willebrand factor antigen; VWF:CBA, VWF
collagen binding activity.
Note: Comparison according to peak severity.
a
p -Values were obtained for nominal variables by the chi-square test, for continuous
variables by the Kruskal–Wallis test. Only severity subgroups of hospitalized patients
were compared by the above statistical tests. Results of control patients are shown
for reference only; this group was not included in the statistical analyses. NA: not
applicable/not available. Missing data were not involved in the calculation of percentages.
For laboratory markers reference ranges are indicated in brackets.
b Other comorbidities included: acute myocardial infarction, stroke, chronic renal
failure, chronic psychiatric diseases, dementia, epilepsy, sclerosis multiplex, Alzheimer's
disease, acute myeloid leukemia, chronic lymphoid leukemia, and human immunodeficiency
virus (HIV) infection.
The patients' age and the number of comorbidities were higher in patients who later
died, and several complications (respiratory failure, macrothromboembolic complications
and acute kidney injury) were more frequent in severe cases (i.e., in patients who
were treated in the ICU and/or died) compared with other patients.
Neutrophil granulocyte counts were higher, whereas lymphocyte counts were lower in
severe cases. Markers and mediators of inflammation (CRP and IL-6) gradually increased
in parallel with increasing severity of COVID-19.
Platelet counts were in the normal range or slightly decreased and did not differ
significantly across severity subgroups or from patient controls. Prothrombin time
showed a gradual increase in parallel with increasing disease severity. Thrombin time
was prolonged in fatal cases. D-dimer levels were significantly elevated in all groups
of hospitalized COVID-19 patients in comparison to patient controls, with 90.2% of
hospitalized COVID-19 patients' values above the upper limit of normal range. Fibrinogen
levels showed a gradual increase across the HOSP, HOSP + O2, and ICU groups, with
81.2% of patients in the ICU group having elevated fibrinogen levels. However, there
was a drop in fibrinogen levels in multiple fatal cases: 40.0% of patients in the
FATAL group had normal or slightly decreased fibrinogen levels.
von Willebrand Factor Antigen, Collagen Binding Activity, ADAMTS13 Activity, and Their
Ratio in COVID-19 Disease
[Fig. 1 ] shows VWF:Ag concentration, VWF:CBA, ADAMTS13:Ac, and their ratios in patients classified
according to the peak severity of COVID-19 disease.
Fig. 1 von Willebrand factor (VWF) antigen (VWF:Ag), VWF collagen binding activity (VWF:CBA),
a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13
activity (ADAMTS13:Ac), and their ratios in groups based on the peak severity of the
COVID-19 disease. Median and interquartile ranges are plotted. The dotted lines indicate
the upper and lower limits of the normal range; the gray area below the dashed line
on panel D indicates severe ADAMTS13 deficiency. (p -values of Dunn's multiple comparison tests below 0.05 are shown.)
The levels of VWF:Ag and VWF:CBA showed a gradual increase in parallel with increased
disease severity. Roughly half of the patients in the HOSP group had VWF:Ag levels
above the upper limit of the reference range (200%), whereas VWF:Ag concentrations
were increased in almost all fatal cases. The VWF:CBA/VWF:Ag ratios in groups of hospitalized
COVID-19 patients did not differ significantly from each other and from those of control
subjects.
ADAMTS13:Ac markedly decreased in severe COVID-19 cases (FATAL and ICU groups), whereas
it was normal or only slightly decreased in cases of moderate severity (HOSP and HOSP + O2).
The proportion of patients with ADAMTS13:Ac levels below the lower limit of the reference
range (67%) was around 30% in moderate cases, 70.6% in the ICU group, and 84.0% in
the FATAL group. It is important to note, however, that none of the hospitalized COVID-19
patients had severely deficient (< 10%) ADAMTS13:Ac values.
In consequence of the above changes, the VWF:Ag/ADAMTS13:Ac and VWF:CBA/ADAMTS13 ratios
increased across groups in parallel with disease severity: the median VWF:Ag/ADAMTS13:Ac
ratio was over five times higher in the FATAL group compared with the HOSP group.
Associations of von Willebrand Factor Levels and ADAMTS13 Activity with Laboratory
and Clinical Parameters
The above parameters—VWF:Ag, VWF:CBA, ADAMTS13:Ac, and VWF:Ag/ADAMTS13:Ac ratio—correlated
with several laboratory parameters associated with disease severity. These correlations
are presented in detail in [Supplementary Table S2 ] (available in the online version).
Briefly, VWF:Ag levels showed moderate positive correlations (Spearman's r > 0.3, p < 0.01) with markers of inflammation (CRP, procalcitonin, ferritin), urea, and lactate
dehydrogenase. ADAMTS13:Ac inversely correlated (Spearman's r < –0.3, p < 0.01) with the above parameters as well as with neutrophil granulocyte count, D-dimer,
red blood cell distribution width, and IL-6 values. In addition, ADAMTS13:Ac showed
moderate positive correlations with the lymphocyte count, red blood cell count, and
hemoglobin levels, with the activity of the complement alternative pathway and with
the concentrations of its components and regulators (C3, factor I, factor H).
Interestingly, apart from the above described moderate inverse correlation between
ADAMTS13:Ac and D-dimer level, neither ADAMTS13:Ac nor VWF:Ag or VWF:CBA correlated
with other parameters of hemostasis and coagulation (platelet count, prothrombin time,
activated partial thromboplastin time, thrombin time, or fibrinogen level).
ADAMTS13:Ac was lower, whereas VWF:CBA was higher in patients older than 67 years
(median age in the cohort). Furthermore, ADAMTS13:Ac tended to be lower in patients
with acute kidney injury (KDIGO 2 or 3), and was significantly lower in patients with
malignant diseases ([Supplementary Table S3 ], available in the online version). After stratification according to disease severity
and age or malignancy, we found that the differences in ADAMTS13:Ac, VWF:Ag, or VWF:CBA
were not statistically significant in any subgroup ([Supplementary Figs. S2 ] and [S3 ], available in the online version). There was no difference in the VWF:Ag, VWF:CBA,
or ADAMTS13:Ac values between severe COVID-19 patients with and without macrothromboembolic
complications.
von Willebrand Factor Antigen, Collagen Binding Activity, and ADAMTS13 Activity as
Biomarkers of Disease Severity
To assess the potential of VWF:Ag, VWF:CBA, and ADAMTS13:Ac as biomarkers of COVID-19
disease severity, we divided the patients into two groups (in accordance with the
WHO Ordinal Scale for Clinical Improvement): fatal cases and cases necessitating ICU
admission were considered severe (ICU and FATAL groups, n = 42), whereas other cases requiring hospitalization (HOSP and HOSP + O2 groups,
n = 60) were considered of moderate severity. Laboratory results of mild and severe
cases are summarized in [Table 2 ].
Table 2
Laboratory data of mild (HOSP and HOSP + O2) and severe (ICU and FATAL) COVID-19 cases
Variables
Mild
(HOSP/HOSP + O2)
n = 60
Severe
(ICU/FATAL)
n = 42
p -Value[a ]
Neutrophil granulocyte count (2–7.5 G/L)
3.8 (2.8–5.8)
5.6 (3.2–9.4)
0.0022
Lymphocyte count (1.5–4 G/L)
1.5 (1.0–2.0)
0.9 (0.6–1.2)
< 0.0001
Interleukin 6 (2–4.4 pg/mL)
16.9 (6.2–45.1)
47.8 (20.4–197.0)
0.0001
C-reactive protein (< 10 mg/L)
24.1 (8.4–73.5)
123.9 (54.9–195.4)
< 0.0001
Platelet count (150–400 G/L)
242 (189–349)
222 (147–285)
0.0602
INR (0.9–1.15)
1.02 (0.98–1.10)
1.15 (1.06–1.38)
0.0002
Fibrinogen (2.8–4.7 g/L)
5.3 (4.4–6.4)
6.0 (4.1–6.9)
0.5234
D-dimers (< 500 ng/mL)
1,105 (580–1,752)
1,620 (1,090–3,090)
0.0024
Complement parameters
Classical pathway (48–103 CH50/mL)
77 (67–89)
71 (48–85)
0.0678
Lectin pathway (35–125%)
73 (6–141)
56 (6–134)
0.7529
Alternative pathway (70–125%)
94 (79–107)
80 (58–96)
0.0038
C3 (0.9–1.8 g/L)
1.31 (1.13–1.48)
1.12 (0.86–1.37)
0.0050
C4 (0.15–0.55 g/L)
0.37 (0.29–0.46)
0.29 (0.21–0.51)
0.1530
sC5b9 (110–252 ng/mL)
268 (192–372)
364 (242–529)
0.0203
C3a (70–270 ng/mL)
220 (134–294)
353 (216–511)
0.0001
C3a/C3 (ng/mg)
154 (113–225)
316 (186–565)
< 0.0001
VWF and ADAMTS13
VWF:Ag (50–200%)
242 (175–335)
382 (292–523)
< 0.0001
VWF:CBA (%)
193 (141–250)
274 (199–412)
0.0002
VWF:CBA/VWF:Ag
0.84 (0.69–1.00)
0.80 (0.60–0.97)
0.6155
ADAMTS13:Ac (67–150%)
81 (64–114)
49 (34–57)
< 0.0001
VWF:Ag/ADAMTS13:Ac
3.0 (1.9–4.3)
9.4 (4.2–14.2)
< 0.0001
VWF:CBA/ADAMTS13:Ac
2.3 (1.5–3.6)
6.4 (3.5–11.9)
< 0.0001
Abbreviations: ADAMTS13:Ac, a disintegrin and metalloproteinase with a thrombospondin
type 1 motif, member 13 activity; HOSP, hospitalized, no oxygen support; HOSP + O2,
hospitalized, with nasal oxygen support; ICU, intensive care unit; INR, international
normalized ratio; VWF:Ag, von Willebrand factor antigen; VWF:CBA, VWF collagen binding
activity.
a
p -Values of the Mann–Whitney U test are shown.
Based on the median values of VWF:Ag (294%), VWF:CBA (212%), and ADAMTS13:Ac (67%)
in our cohort, we chose 300% as a cutoff value for VWF:Ag, 200% for VWF:CBA, and 67%
for ADAMTS13:Ac; the latter coincided with the lower limit of the ADAMTS13:Ac reference
range. According to the results of ROC curve analysis, these cutoff values were almost
optimal for distinguishing between moderate and severe COVID-19 cases ([Supplementary Fig. S4 ], available in the online version).
According to the results of logistic regression analysis, we found that patients with
VWF:Ag above 300%, VWF:CBA above 200%, or ADAMTS13:Ac below 67% were 5.91 (95% confidence
interval [CI]: 2.34–14.93), 3.23 (1.31–7.98), and 8.56 (3.37–21.73) times more likely
to have severe COVID-19 disease, respectively, when compared with other patients ([Fig. 2A ], [Supplementary Table S4 ], available in the online version). Importantly, VWF:Ag and ADAMTS13:Ac remained
significant indicators of disease severity in multivariable models even after adjusting
for a baseline model consisting of age, the number of comorbidities, and CRP concentrations.
The VWF:Ag/ADAMTS13:Ac ratio was not superior to ADAMTS13:Ac alone in differentiating
between severe and moderate COVID-19 cases.
Fig. 2 Associations of low a disintegrin and metalloproteinase with a thrombospondin type
1 motif, member 13 activity (ADAMTS13:Ac) and high von Willebrand factor (VWF) antigen
(VWF:Ag) or VWF collagen binding activity (VWF:CBA) values with the risk of developing
severe disease (A ) and with the risk of in-hospital mortality (B ). ADAMTS13:Ac values below 67% were considered low, whereas VWF:Ag concentrations
above 300%, VWF:CBA values above 200%, and VWF:Ag/ADAMTS13:Ac ratios above 5 were
considered high. Fatal cases and cases requiring intensive care were regarded as severe.
Odds ratios of logistic regression models (A ), hazard ratios of Cox proportional hazard models (B ), and their 95% confidence intervals (95% CIs) are shown. Results of multivariable
regression models in which each of the above variables were adjusted for a baseline
model (adj) including age (in decades), number of comorbidities, and C-reactive protein
(CRP) level (grouped according to median and quartiles) are shown in blue. (Results
of the above logistic and Cox regression models are also presented as tables—in [Supplementary Tables S4 ] and [S5 ], respectively.)
von Willebrand Factor Antigen, Collagen Binding Activity, and ADAMTS13 Activity as
Predictors of In-Hospital Mortality
Twenty-five COVID-19 patients in our study cohort died during the hospital stay, which
means that the overall in-hospital mortality was 24.5%. Laboratory parameters of survivors
and nonsurvivors are summarized in [Table 3 ].
Table 3
Laboratory data of COVID-19 patients who later survived or deceased
Variables
Survived
(HOSP/HOSP + O2/ICU)
n = 77
Deceased
(FATAL)
n = 25
p -Value[a ]
Neutrophil granulocyte count (2–7.5 G/L)
3.9 (2.9–5.9)
6.0 (4.2–10.3)
0.0050
Lymphocyte count (1.5–4 G/L)
1.4 (0.9–1.9)
0.8 (0.5–1.1)
0.0002
Interleukin 6 (2–4.4 pg/mL)
19.0 (6.9–48.7)
90.4 (34.6–267.3)
< 0.0001
C-reactive protein (< 10 mg/L)
36.8 (10.8–97.4)
149.1 (54.9–196.8)
0.0002
Platelet count (150–400 G/L)
237 (188–306)
194 (131–285)
0.0592
INR (0.9–1.15)
1.05 (0.98–1.14)
1.17 (1.07–1.48)
0.0032
Fibrinogen (2.8–4.7 g/L)
5.7 (4.6–6.8)
5.0 (3.9–6.5)
0.2696
D-dimers (< 500 ng/mL)
1,140 (610–1,900)
1,430 (1,106–4,380)
0.0102
Complement parameters
Classical pathway (48–103 CH50/mL)
74 (66–89)
63 (44–80)
0.0084
Lectin pathway (35–125%)
72 (4–141)
56 (9–134)
0.7513
Alternative pathway (70–125%)
94 (80–103)
60 (35–87)
< 0.0001
C3 (0.9–1.8 g/L)
1.31 (1.11–1.49)
1.05 (0.66–1.20)
< 0.0001
C4 (0.15–0.55 g/L)
0.37 (0.26–0.48)
0.27 (0.16–0.43)
0.0468
sC5b9 (110–252 ng/mL)
281 (203–410)
364 (246–498)
0.1288
C3a (70–270 ng/mL)
237 (141–337)
375 (196–459)
0.0095
C3a/C3 (ng/mg)
179 (123–271)
337 (266–651)
< 0.0001
VWF and ADAMTS13
VWF:Ag (50–200%)
257 (195–365)
387 (304–496)
0.0002
VWF:CBA (%)
205 (151–272)
298 (199–433)
0.0058
VWF:CBA/VWF:Ag
0.83 (0.69–1.01)
0.80 (0.55–0.94)
0.3812
ADAMTS13:Ac (67–150%)
74 (55–106)
43 (32–56)
< 0.0001
VWF:Ag/ADAMTS13:Ac
3.5 (2.1–5.5)
11.4 (5.8–13.8)
< 0.0001
VWF:CBA/ADAMTS13:Ac
2.7 (1.7–4.2)
7.0 (4.5–12.6)
< 0.0001
Abbreviations: ADAMTS13:Ac, a disintegrin and metalloproteinase with a thrombospondin
type 1 motif, member 13 activity; HOSP, hospitalized, no oxygen support; HOSP + O2,
hospitalized, with nasal oxygen support; ICU, intensive care unit; INR, international
normalized ratio; VWF:Ag, von Willebrand factor antigen; VWF:CBA, VWF collagen binding
activity.
a
p -Values of the Mann–Whitney U test are shown.
ADAMTS13:Ac was significantly lower, whereas VWF:Ag and VWF:CBA were significantly
higher in samples of patients who later deceased, compared with survivors.
The above results suggest that these parameters might prove to be useful biomarkers
for predicting the in-hospital mortality of hospitalized COVID-19 patients ([Supplementary Fig. S5 ], available in the online version).
Indeed, in-hospital mortality was higher in patients with ADAMTS13:Ac below 67% (41.2%
vs. 7.8%, p < 0.0001) or with VWF:Ag levels above 300% (39.1% vs. 12.5%, p = 0.004), compared with other patients. The difference between patients with low
and high VWF:CBA levels was not statistically significant. Kaplan–Meier curves showing
cumulative survival in the above groups are shown in [Fig. 3 ].
Fig. 3 Mortality in patients according to a disintegrin and metalloproteinase with a thrombospondin
type 1 motif, member 13 activity (ADAMTS13:Ac), von Willebrand factor (VWF) antigen
(VWF:Ag), VWF collagen binding activity (VWF:CBA), and VWF:Ag/ADAMTS13:Ac ratio. Kaplan–Meier
curves (in-hospital mortality plotted against time from hospital admission to death
or last follow-up) for patients above and below 67% ADAMTS13:Ac (A ), 300% VWF:Ag (B ), 200% VWF:CBA (C ), and a VWF:Ag/ADAMTS13:Ac ratio of 5 (D ) are shown.
Finally, we generated Cox proportional hazard models to analyze the effect of decreased
(< 67%) ADAMTS13:Ac and elevated VWF:Ag (> 300%) and VWF:CBA (> 200%) levels on the
in-hospital mortality of COVID-19 patients. The hazard ratio was 5.59 (95% CI: 1.92–16.32)
for decreased ADAMTS13:Ac and 3.31 (1.31–8.34) for increased VWF:Ag ([Fig. 2B ], [Supplementary Table S5 ], available in the online version) in univariable models.
However, the increased VWF:Ag and decreased ADAMTS13:Ac levels did not prove to be
significant independent predictors of in-hospital mortality after adjusting to the
above described baseline model including age, the number of comorbidities, and CRP
concentration. The VWF:CBA was not a significant predictor, whereas the VWF:Ag/ADAMTS13:Ac
ratio was similar to ADAMTS13:Ac alone in predicting in-hospital mortality.
The Concomitant Presence of Decreased ADAMTS13 Activity and Increased Complement Activation
as a Predictor of Severity and In-Hospital Mortality
Previously we described that the level of C3a—marker of complement activation and
anaphylatoxin—was increased, whereas the level of complement factor C3 was decreased
in fatal COVID-19 cases.[29 ] We found that patients with a C3a/C3 ratio over 200 ng/mg—indicating complement
overactivation and consumption—had a higher risk of death compared with other patients.
Along these lines, we investigated whether there is a relationship between ADAMTS13:Ac,
complement overactivation and consumption, and the severity and outcome of COVID-19.
Accordingly, we applied stratified multivariable statistical analyses with interaction
terms. Hospitalized patients were divided into four subgroups based upon their ADAMTS13:Ac
and C3a/C3 ratio. The subgroups are described in detail in [Table 4 ].
Table 4
Characteristics of hospitalized COVID-19 patients in subgroups with different combinations
of normal (> 67%) or low (< 67%) ADAMTS13:Ac and low (< 200 ng/mg) or high (> 200 ng/mg)
complement C3a/C3 ratio
Variables
ADAMTS13:Ac normal,
C3a/C3 low
n = 29
ADAMTS13:Ac normal,
C3a/C3
high
n = 22
ADAMTS13:Ac low,
C3a/C3 low
n = 22
ADAMTS13:Ac low,
C3a/C3 high
n = 27
p -Value[a ]
Male sex, % (n )
62.1 (18)
50.0 (11)
59.1 (13)
48.1 (13)
0.690
Age (median, IQR)
57 (40–66)
67 (58–74)
66 (54–70)
76 (69–79)
< 0.001
Comorbidities
Total number of comorbidities (median, IQR)
2 (1–3)
2.5 (1–3)
2 (1–3)
3 (2–5)
0.042
Hypertension, % (n )
58.6 (17)
63.6 (14)
59.1 (13)
74.1 (20)
0.618
Chronic pulmonary disease, % (n )
13.8 (4)
31.8 (7)
22.7 (5)
22.2 (6)
0.497
Diabetes mellitus, % (n )
20.7 (6)
27.3 (6)
13.6 (3)
33.3 (9)
0.409
Chronic heart disease, % (n )
31.0 (9)
27.3 (6)
22.7 (5)
48.1 (13)
0.238
Malignant disease, % (n )
3.4 (1)
9.1 (2)
31.8 (7)
48.1 (13)
< 0.001
Presenting symptoms
Delay between first symptom and sampling, days (median, IQR)
12 (6–25)
8 (5–19)
9 (5–14)
10 (4–27)
0.858
Complications
Respiratory failure necessitating mechanical ventilation, % (n )
6.9 (2)
18.2 (4)
13.6 (3)
70.4 (19)
< 0.001
Macrothromboembolic complications, % (n )
0.0 (0)
18.2 (4)
4.5 (1)
7.4 (2)
0.085
Acute kidney injury (KDIGO: 2–3), % (n )
3.4 (1)
13.6 (3)
4.5 (1)
25.9 (7)
0.042
Transfer to ICU, % (n )
6.9 (2)
27.3 (6)
31.8 (7)
77.8 (21)
< 0.001
Death, % (n )
6.9 (2)
9.1 (2)
9.1 (2)
66.7 (18)
< 0.001
Laboratory findings (median, IQR)
Neutrophil granulocyte count (2–7.5 G/L)
3.5 (2.8–4.5)
4.3 (2.8–6.1)
4.6 (3.2–5.9)
6.0 (4.2–10.4)
0.007
Lymphocyte count (1.5–4 G/L)
1.8 (1.0–2.1)
1.1 (0.9–1.7)
1.0 (0.9–1.5)
1.0 (0.7–1.4)
0.008
Interleukin 6 (2–4.4 pg/mL)
12.5 (6.0–41.2)
24.5 (12.8–72.2)
29.1 (19.0–50.3)
50.0 (14.0–265.0)
0.040
C-reactive protein (< 10 mg/L)
15 (6–41)
77 (30–145)
45 (14–108)
149 (42–195)
< 0.001
Platelet count (150–400 G/L)
233 (192–282)
236 (129–388)
236 (173–348)
204 (163–285)
0.545
INR (0.9–1.15)
1.05 (0.98–1.11)
1.02 (0.98–1.20)
1.06 (0.98–1.15)
1.12 (1.06–1.47)
0.142
Fibrinogen (2.8–4.7 g/L)
5.1 (4.2–6.6)
5.0 (4.0–6.6)
5.8 (4.9–7.6)
5.7 (4.4–6.5)
0.700
D-dimers (< 500 ng/mL)
1,030 (530–1,850)
1,547 (512–1,996)
1,480 (879–3,090)
1,366 (1,079–3,398)
0.164
VWF:Ag, % (50–200%)
247 (160–332)
266 (222–317)
240 (136–396)
392 (292–543)
< 0.001
VWF:CBA, %
192 (137–233)
199 (146–241)
193 (145–338)
332 (200–461)
< 0.001
VWF:CBA / VWF:Ag
0.86 (0.71–1.01)
0.70 (0.55–0.88)
0.95 (0.75–1.06)
0.82 (0.68–0.99)
0.052
Abbreviations: ADAMTS13:Ac, a disintegrin and metalloproteinase with a thrombospondin
type 1 motif, member 13 activity; ICU, intensive care unit; INR, international normalized
ratio; IQR, interquartile range; VWF:Ag, von Willebrand factor antigen; VWF:CBA, VWF
collagen binding activity.
Note: Two patients had missing C3a data; these patients were not included in any of
the subgroups. Other comorbidities included are listed below [Table 1 ]. Reference ranges of laboratory markers are indicated in brackets.
a
p -Values were obtained by the chi-square test for nominal variables, and by the Kruskal–Wallis
test for continuous variables.
Peak disease severity according to ADAMTS13:Ac and C3a/C3 values are shown in [Fig. 4A ]. Respiratory failure requiring intubation and mechanical ventilation was more frequent
in the group of patients who had low ADAMTS13:Ac and high C3a/C3 ratio in comparison
with the other groups (70.4% vs. 6.9%, 18.4%, and 13.6%, odds ratio > 10 and p < 0.0004 for each comparison).
Fig. 4 Peak disease severity and in-hospital mortality in patients with different combinations
of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member
13 activity (ADAMTS13:Ac) and C3a/C3 ratio, a marker of complement activation and
consumption. Peak disease severity according to ADAMTS13:Ac and C3a/C3 ratio is shown
on (A ). Lines indicate the median-based cutoff values of ADAMTS13:Ac (67%) and C3a/C3 (200 ng/mg)
that were used to define subgroups with low or high values. High (normal) ADAMTS13:Ac
and low C3a/C3 ratio are regarded as physiological, whereas low ADAMTS13:Ac and high
C3a/C3 ratio are considered pathological. The proportions of deceased patients in
each quartile are indicated in text boxes. (B ) Kaplan–Meier curves (in-hospital mortality plotted against time) in the four subgroups.
The survival in the low ADAMTS13:Ac and high C3a/C3 subgroup is significantly different
from those of other subgroups (p < 0.0001, p = 0.0001, and p < 0.0001, by pairwise log-rank comparisons), whereas it did not differ between the
other three subgroups (p = 0.8369, p = 0.8865, and p = 0.9052). Colors of the curves match those of text boxes on panel A . (C ) Results of multivariable Cox proportional hazard ratio models composed of low ADAMTS13:Ac,
high C3a/C3 ratio, and their statistical interaction. The model was adjusted to the
baseline model composed of age, the number of comorbidities, and the C-reactive protein
(CRP) level; results of the adjusted model are shown in blue.
In-hospital mortality was also considerably higher in the former subgroup than in
any other subgroup (66.7% vs. 6.9%, 9.1%, and 9.1%; odds ratio > 19 and p < 0.0001 for each comparison).
In contrast, isolated low ADAMTS13:Ac or elevated C3a/C3 ratio, alone, were not associated
with increased risk of respiratory failure or death.
Kaplan–Meier curves presented in [Fig. 4B ] show that the cumulative survival in patients with low ADAMTS13:Ac and high C3a/C3
ratio is clearly distinct from those of all other groups.
These results indicate that there is a statistical interaction between the above parameters:
low ADAMTS13:Ac increases the risk of in-hospital mortality only in the setting of
a high C3a/C3 ratio. To test how adjusting for our baseline model (consisting of age,
number of comorbidities, and CRP level) influences the above statistical interaction,
we prepared multivariable Cox proportional hazard models with interaction terms (presented
in [Fig. 4C ] and [Supplementary Table S6 ], available in the online version). Our results demonstrate that adjusting for our
baseline model did not affect the association of the statistical interaction between
low ADAMTS13:Ac and high C3a/C3 ratio with in-hospital mortality.
Discussion
Our study provides the first observational evidence that the concomitant presence
of decreased ADAMTS13:Ac and increased markers of complement activation is associated
with COVID-19 severity and mortality. These results suggest that a potential interaction
between the VWF-ADAMTS13 axis and complement activation may be a key factor in the
pathogenesis of COVID-19.
First, to investigate the role of the VWF-ADAMTS13 axis in the pathogenesis of COVID-19,
we measured ADAMTS13:Ac, VWF:Ag, and VWF:CBA levels in a cohort of 102 hospitalized
COVID-19 patients of various disease severity and in a control group of 26 convalescent
plasma donors.
We found that VWF:Ag and VWF:CBA levels were elevated in all groups of hospitalized
COVID-19 patients; there was a continuous increase in these parameters in parallel
with increasing COVID-19 severity. ADAMTS13:Ac, on the other hand, decreased in parallel
with disease severity; most patients with severe COVID-19 (i.e., those who deceased
or required intensive care) had ADAMTS13:Ac values below the lower limit of the normal
range (67%). As a consequence of the above alterations, the VWF:Ag/ADAMTS13:Ac ratio—indicating
the functional state of the VWF-ADAMTS13 axis—increased considerably, exceeding 10
in the group of nonsurvivors. The VWF:CBA/VWF:Ag ratio was variable, and did not differ
significantly between groups based on disease severity. Severe ADAMTS13 deficiency
was not observed in our cohort, in contrast to cases of thrombotic thrombocytopenic
purpura patients with concomitant COVID-19 disease.[33 ]
As ADAMTS13:Ac was significantly lower and VWF:Ag and VWF:CBA were significantly higher
in severe COVID-19 cases and in nonsurvivors than in moderate cases and in survivors,
respectively, we assessed the potential of the above parameters as biomarkers of severity
and as predictors of in-hospital mortality in hospitalized COVID-19 patients.
We found that patients with VWF:Ag levels over 300% and those with ADAMTS13:Ac below
the lower limit of normal (67%) were 5.91 and 8.56 times more likely to have severe
COVID-19 disease, whereas the risk of in-hospital mortality was 3.31 and 5.59 times
higher in these groups, respectively. When adjusting for a baseline model composed
of key clinical and laboratory parameters associated with the severity or mortality
of COVID-19—age, number of comorbidities, and CRP concentration—decreased ADAMTS13:Ac
and elevated VWF:Ag level remained significant predictors of disease severity, but
were no longer significant predictors of in-hospital mortality.
Our results regarding the elevated VWF:Ag concentrations and the moderately decreased—but
not deficient—ADAMTS13:Ac are in line with results described in other cohorts of hospitalized
COVID-19 patients.[11 ]
[12 ]
[14 ]
[15 ]
[16 ]
[19 ]
[20 ]
[21 ]
[34 ]
[35 ]
[36 ]
[37 ]
[38 ]
[39 ] The observations that the increase of VWF:Ag and the decrease of ADAMTS13:Ac were
more pronounced in severe/critical COVID-19 than in moderate cases, and that elevated
VWF:Ag and reduced ADAMTS13:Ac are thus predictors of in-hospital mortality in COVID-19,
are also in agreement with results of previous studies.[11 ]
[14 ]
[15 ]
[16 ]
[18 ]
[19 ]
[20 ]
[21 ]
[37 ]
[38 ]
[39 ]
Taken together, our results support that the VWF-ADAMTS13 axis is involved in the
pathogenesis of the COVID-19 disease. The hypoxic and inflammatory state characteristic
for severe COVID-19 can increase the secretion and interfere with the cleavage of
VWF by multiple mechanisms.[40 ]
[41 ] In particular, there is emerging evidence supporting the role of neutrophil granulocyte
activation and the release of neutrophil extracellular traps (NETosis) in the pathogenesis
of COVID-19[42 ]
[43 ]; these processes may also affect the VWF-ADAMTS13 axis through the oxidative modification,
sialylation or citrullination of its components, or by otherwise interfering with
their interaction.[44 ]
[45 ]
[46 ]
[47 ]
[48 ] If their cleavage is hindered by the above mechanisms, persisting ultra-large VWF
multimers form large strings that are capable of binding platelets firmly.[49 ]
However, the ultra-large VWF multimers provide an ideal surface not only for platelet
adhesion, but also for complement activation.[50 ] Complement deposition in lung capillaries,[51 ] and increased plasma levels of complement activation products support the activated
state of the complement system in COVID-19.[27 ]
[29 ]
[52 ] The concentrations of the activation products were found to be higher in severe
COVID-19 patients,[27 ]
[29 ]
[52 ] indicating that excessive complement activation is more likely in these cases. Furthermore,
levels of complement activation products correlated with those of VWF and other markers
of endothelial perturbation,[52 ] supporting that there is a link between endothelial VWF secretion and complement
activation.
Complement activation on the surface of endothelial cell-bound ultra-large VWF multimers[50 ] or exposure to complement activation products—C3a, C5a, C5b-9—induce prothrombotic
and proinflammatory changes in endothelial cells, also termed as endothelial dysfunction.[53 ]
[54 ]
[55 ] The consequentially increased release of VWF and the decreased expression of thrombomodulin
further enhance complement activation and endothelial dysfunction.[56 ] In addition to this direct positive feedback loop, there is another one involving
platelets and neutrophil granulocytes. Complement activation products are able to
activate platelets, neutrophil granulocytes, and macrophages.[57 ] Platelet-decorated VWF strings provide an ideal scaffold for the adhesion of neutrophil
granulocytes.[58 ] If the neutrophils are preactivated, this may be followed by NETosis, which in turn
induces tissue factor expression and thus augments the thrombotic potential of endothelial
cells.[59 ]
In conclusion, if ultra-large VWF molecules are not cleaved upon release, the endothelial
VWF secretion and complement activation amplify each other, eventually leading to
immunothrombosis, a major cause of mortality in COVID-19.[60 ] ADAMTS13, however, is able to break this vicious circle by cleaving the highly adhesive
ultra-large VWF multimers.
Based on the above, we hypothesized, that the decrease of ADAMTS13:Ac would be more
detrimental in the case of excessive complement activation—providing positive feedback
in the above described ways—than in a setting of a well-regulated complement system.
To test this hypothesis, we compared disease outcomes in groups of hospitalized COVID-19
patients with different combinations of normal or decreased ADAMTS13:Ac and low or
high levels of C3a/C3 ratios.
The C3a/C3 ratio was introduced in our previous analysis of the same cohort[29 ] as a general marker of complement overactivation and consumption. Complement C3
is the central molecule of the complement system: all—the classical, lectin, and alternative—activation
pathways converge on the level of C3. Upon its activation, the soluble C3a fragment
is released, which is therefore a good indicator of complement activation. However,
the absolute concentration of C3a is dependent on the concentration of available C3
molecules. C3 concentrations, in turn, were found to moderately increase in parallel
with disease severity—probably in consequence of the acute phase reaction—and then
suddenly drop in fatal cases, due to complement consumption.[29 ] Based on the above, we hypothesized that the C3a/C3 ratio better reflected the activated
state of the complement system than C3a concentration alone. In line with this hypothesis,
the C3a/C3 ratio proved to be a stronger predictor of in-hospital mortality of COVID-19
patients in comparison to C3a in our previous study.
Most importantly, when we compared groups with different ADAMTS13:Ac and C3a/C3 ratios,
we found that the frequency of respiratory failure and in-hospital death was indeed
markedly higher in the group of patients who had decreased ADAMTS13:Ac and signs of
excessive complement activation at the same time, whereas decreased ADAMTS13:Ac or
increased complement activation alone were not found to be associated with increased
disease severity or mortality. Adjusting to our baseline model did not influence the
above described association between in-hospital mortality and the combination of low
ADAMTS13:Ac and high C3a/C3 ratio. Interestingly, VWF:Ag concentration and VWF:CBA
were also significantly higher in the group of patients with both low ADAMTS13:Ac
and high C3a/C3 ratio, whereas it did not differ between the other subgroups ([Table 4 ]). This result supports that endothelial activation and increased VWF secretion might
be a key link between decreased ADAMTS13:Ac, complement overactivation, and the severity
of COVID-19.
The main strengths of our cohort were the concurrent determination of VWF:Ag, ADAMTS13:Ac,
and the detailed characterization of the complement profile, which allowed us to investigate
the interactions of the VWF-ADAMTS13 axis and complement activation. Our cohort, as
a whole, represented a broad spectrum of COVID-19 severity, which, however, was divided
into multiple, relatively homogenous subgroups. This enabled a detailed analysis of
associations between COVID-19 severity and different laboratory parameters. As follow-up
was complete in all cases, we were able to formally evaluate mortality in survival
models. All relevant clinical and laboratory data were collected, which enabled us
to adjust for the most important confounders.
A potential limitation of our study is its relatively small sample size of 102 patients.
However, the subgroups based upon disease severity were nearly equal, which allowed
us to perform reliable statistical analyses. Forming groups based on multiple variables,
however, leads to subgroups with low numbers of individuals; results of statistical
analyses have to be interpreted with caution in these cases.
A further limitation of our study was the high proportion of patients with malignant
diseases, especially among cases with severe disease. However, there were no significant
differences in ADAMTS13 or VWF levels between patients with and without malignant
diseases in any severity subgroup. Thus, the lower ADAMTS13:Ac and higher VWF:Ag and
VWF:CBA values observed in groups of higher severity are not attributable to the higher
proportion of patients with malignant diseases in these groups. Accordingly, adjusting
our models for the presence or absence of malignant diseases did not influence our
results.
Furthermore, the median age was lower in control subjects and was higher in patients
who subsequently died due to COVID-19 disease (FATAL group) compared with other groups.
However, stratified analyses by disease severity showed no significant differences
between patients below and above 67 years in any given subgroup. Furthermore, we adjusted
all our models of severity or survival for a baseline model consisting of age, number
of comorbidities, and CRP level.
Finally, it has to be noted that data on anticoagulation were not collected for all
patients, although such treatment may have influenced the laboratory values of coagulation.
To conclude, in this study we have shown that the concurrent presence of decreased
ADAMTS13:Ac and increased complement activation is associated with increased in-hospital
mortality in COVID-19 patients. These results suggest that an interaction between
the VWF-ADAMTS13 axis and complement system plays an important role in the pathogenesis
of severe COVID-19 disease, most probably via triggering immunothrombosis. The specific
molecular background of the above interaction has yet to be investigated. Importantly,
our results indicate that if either ADAMTS13:Ac is normal or pathological complement
activation is absent, the risk of in-hospital mortality is significantly lower in
COVID-19. This finding raises the possibility of ADAMTS13 replacement therapy in selected
cases with low ADAMTS13:Ac, and underlines the importance of studies on complement
inhibitory drugs in COVID-19.
What is known about this topic?
In a subset of patients infected with the SARS-CoV-2 virus, immunothrombosis develops
in lung microvessels, which is a major cause of respiratory failure and mortality
in COVID-19.
Endothelial perturbation—which is a central event in the development of immunothrombosis—results
in elevated VWF antigen concentrations, whereas ADAMTS13 activity is moderately decreased
in COVID-19 patients.
The complement system is also activated in COVID-19, levels of complement activation
markers correlated with that of VWF and other markers of endothelial activation.
What does this paper add?
In this study, we validated the role of increased VWF antigen concentrations and decreased
ADAMTS13 activity as good markers of severity and predictors of in-hospital mortality,
and we report for the first time that concomitant changes in the VWF-ADAMTS13 axis
and complement activation are associated with the severity and mortality of the COVID-19
disease.
The risk of respiratory failure and of in-hospital mortality is higher in COVID-19
patients with concurrently decreased ADAMTS13 activity and increased C3a/C3 ratio—indicating
complement overactivation and consumption—whereas decreased ADAMTS13 activity or high
C3a/C3 ratio, alone, were not associated with increased risk of respiratory failure
or death.
